These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 24463189)

  • 1. Mechanisms and management of hypertension in autosomal dominant polycystic kidney disease.
    Rahbari-Oskoui F; Williams O; Chapman A
    Nephrol Dial Transplant; 2014 Dec; 29(12):2194-201. PubMed ID: 24463189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal volume, renin-angiotensin-aldosterone system, hypertension, and left ventricular hypertrophy in patients with autosomal dominant polycystic kidney disease.
    Schrier RW
    J Am Soc Nephrol; 2009 Sep; 20(9):1888-93. PubMed ID: 19696226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cardiovascular risk in polycystic kidney disease].
    Di Lorenzo A; Stallone G; Infante B; Grandaliano G; Schena FP
    G Ital Cardiol (Rome); 2015 Sep; 16(9):479-84. PubMed ID: 26418387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypertension in autosomal dominant polycystic kidney disease.
    Chapman AB; Stepniakowski K; Rahbari-Oskoui F
    Adv Chronic Kidney Dis; 2010 Mar; 17(2):153-63. PubMed ID: 20219618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renin-Angiotensin-aldosterone system in autosomal dominant polycystic kidney disease.
    Tkachenko O; Helal I; Shchekochikhin D; Schrier RW
    Curr Hypertens Rev; 2013 Feb; 9(1):12-20. PubMed ID: 23971639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pathogenesis of hypertension in autosomal dominant polycystic kidney disease.
    Wang D; Strandgaard S
    J Hypertens; 1997 Sep; 15(9):925-33. PubMed ID: 9321739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening of QTc interval and global autonomic activity in autosomal dominant polycystic kidney disease and atherosclerotic renal artery stenosis hypertensive patients.
    Lai S; Perrotta AM; Bagordo D; Mazzaferro S; Menè P; Gigante A; Tinti F; Galani A; Cianci R
    Eur Rev Med Pharmacol Sci; 2021 Oct; 25(20):6333-6338. PubMed ID: 34730214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renin-Angiotensin-Aldosterone System Antagonism and Polycystic Kidney Disease Progression.
    Hian CK; Lee CL; Thomas W
    Nephron; 2016; 134(2):59-63. PubMed ID: 27476173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interpretation of renal volume in autosomal dominant polycystic kidney disease and relevant clinical implications.
    Masoumi A; Elhassan E; Schrier RW
    Iran J Kidney Dis; 2011 Jan; 5(1):1-8. PubMed ID: 21189426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in hormonal and renal vascular responses between normotensive patients with autosomal dominant polycystic kidney disease and unaffected family members.
    Barrett BJ; Foley R; Morgan J; Hefferton D; Parfrey P
    Kidney Int; 1994 Oct; 46(4):1118-23. PubMed ID: 7861706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal care of autosomal dominant polycystic kidney disease patients.
    Schrier RW
    Nephrology (Carlton); 2006 Apr; 11(2):124-30. PubMed ID: 16669974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autosomal dominant polycystic kidney disease: role of the renin-angiotensin system in raised blood pressure in progression of renal and cardiovascular disease.
    Lawson CR; Doulton TW; MacGregor GA
    J Renin Angiotensin Aldosterone Syst; 2006 Sep; 7(3):139-45. PubMed ID: 17094050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease.
    Chapman AB; Johnson A; Gabow PA; Schrier RW
    N Engl J Med; 1990 Oct; 323(16):1091-6. PubMed ID: 2215576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathogenesis of hypertension in autosomal dominant polycystic kidney disease.
    Chapman AB; Schrier RW
    Semin Nephrol; 1991 Nov; 11(6):653-60. PubMed ID: 1767138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determinants of Progression in Early Autosomal Dominant Polycystic Kidney Disease: Is it Blood Pressure or Renin-Angiotensin-Aldosterone-System Blockade?
    Brosnahan GM; Abebe KZ; Moore CG; Bae KT; Braun WE; Chapman AB; Flessner MF; Harris PC; Hogan MC; Perrone RD; Rahbari-Oskoui FF; Steinman TI; Torres VE; The Halt Pkd Investigators
    Curr Hypertens Rev; 2018; 14(1):39-47. PubMed ID: 29564978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of renin-angiotensin-aldosterone system and of sympathetic activity in arterial hypertension associated with autosomal dominant polycystic kidney disease.
    Cerasola G; Li Vecchi M; Mulé G; Cottone S; Mangano MT; Andronico G; Contomo A; Parrino IA; Renda F; Pavone G; Scialabba A
    Contrib Nephrol; 1997; 122():22-7. PubMed ID: 9399032
    [No Abstract]   [Full Text] [Related]  

  • 17. Hypertension in autosomal dominant polycystic kidney disease.
    Chapman AB; Gabow PA
    Kidney Int Suppl; 1997 Oct; 61():S71-3. PubMed ID: 9328971
    [No Abstract]   [Full Text] [Related]  

  • 18. Cardiovascular abnormalities in autosomal-dominant polycystic kidney disease.
    Ecder T; Schrier RW
    Nat Rev Nephrol; 2009 Apr; 5(4):221-8. PubMed ID: 19322187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on pathogenesis, management, and treatment of hypertension in autosomal dominant polycystic kidney disease.
    Helal I; Al-Rowaie F; Abderrahim E; Kheder A
    Saudi J Kidney Dis Transpl; 2017; 28(2):253-260. PubMed ID: 28352004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of renin-angiotensin-aldosterone system gene polymorphisms and hypertension-induced end-stage renal disease in autosomal dominant polycystic kidney disease.
    Ramanathan G; Elumalai R; Periyasamy S; Lakkakula B
    Iran J Kidney Dis; 2014 Jul; 8(4):265-77. PubMed ID: 25001132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.